* Sun Pharmaceutical Industries Ltd rises 1.1 percentto near a record high and a second day of gains, after acompetitor raised revenue guidance citing strong sale of ageneric antibiotic also sold by Sun Pharma.* Hikma Pharmaceuticals Plc on Monday raised itsfull-year revenue forecast for the second time in as many monthson strong sales of its generic version of antibioticdoxycycline. * "We expect this product to easily contribute around US$60-80million in sales in FY14 for Sun," Macquarie said in a report onWednesday referring to generic doxycycline. (abhishek.vishnoi@thomsonreuters.com /;abhishek.vishnoi.thomsonreuters.com@reuters.net)
Barclays downgrades Hikma to 'equalweight' on Generics concerns
(Sharecast News) - Barclays downgraded Hikma Pharmaceuticals on Friday to 'equalweight' from 'overweight' and cut the price target to 1,750p from 2,250p as it said a lack of visibility in the generics division was a real concern.
Read more